Observational studyGeneral thoracic and cardiovascular surgery2015
Optimal timing of clopidogrel discontinuation in Japanese patients: platelet aggregation test using the VerifyNow® system.
Observational study in General thoracic and cardiovascular surgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 9 citations in OpenAlex.
- Blood loss after coronary artery bypass by aspirin responsiveness assessed with preoperative VerifyNow aspirin testing.Research and practice in thrombosis and haemostasis · 2021Article
- Intraoperative collection of autologous platelet-rich plasma from the cardiopulmonary bypass circuit upon initiation of extracorporeal circulation.Journal of cardiothoracic surgery · 2021Article
- Novel Antiplatelet Perioperative Bridging Protocol for Lung Lobectomy: A Case Report.The Permanente journal · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe Japanese Circulation Society recommends discontinuation of antiplatelet therapy 7-14 days before major surgery. However, reports on the relationship between the timing of clopidogrel discontinuation and the risk of postoperative bleeding in Japanese subjects are lacking. We assessed the optimal timing of clopidogrel discontinuation before elective surgery using the VerifyNow® P2Y12 assay. In addition, the relationship between preoperative platelet function and risk of postoperative bleeding was evaluated.
methodsStudy 1: Between June 2012 and December 2014, Platelet function was examined by the VerifyNow P2Y12 assay in patients scheduled for cardiac surgery, every other day after clopidogrel cessation. Study 2: We compared the preoperative platelet function, measured by the VerifyNow, with the postoperative bleeding.
resultsStudy 1: Twenty-four patients were included in this study. The mean P2Y12 reaction units (PRU) on Day-0 was 186, and increased significantly to 283 PRU on Day-7 in a time-dependent manner after clopidogrel discontinuation (p = 0.001). The mean PRU value significantly exceeded the cutoff of 230 on Day-5. Study 2: Correlation between the preoperative aspirin reaction units (ARU) and postoperative bleeding showed a slight inverse correlation in patients undergoing aortic valve replacement (rS = -0.363, p = 0.013), mitral valve plasty (rS = -0.300, p = 0.085) and off-pump coronary artery bypass (rS = -0.176, p = not significant).
conclusionPlatelet aggregation had already recovered at 5 days after clopidogrel cessation. Surgeons could consider decreasing the interval from clopidogrel discontinuation to surgery from the recommended 7-14 days. The VerifyNow assay can be used to predict the risk of perioperative bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.